Cannabinoids Show Early Bone-Building Potential

Research on cannabinoids and bone health has produced intriguing findings, but it has not yet shown that medical marijuana can prevent or treat osteoporosis in people.

Osteoporosis is a disease in which bone mineral density and bone strength decline, increasing the risk of fractures. It is often called a “silent” disease because many people have no symptoms until a fracture occurs. Although back pain, loss of height and a stooped posture can result from spinal fractures, these are consequences of the disease rather than typical early symptoms. The National Institute of Arthritis and Musculoskeletal and Skin Diseases’ overview of osteoporosis identifies age, hormonal changes, family history, certain medical conditions and medications, smoking, heavy alcohol use and physical inactivity as risk factors.

Standard care focuses on reducing fracture risk through weight-bearing and strength exercises, adequate nutrition, fall prevention and, when appropriate, approved medications that slow bone loss or stimulate bone formation. Cannabinoids are not a substitute for evaluation or established osteoporosis treatment.

What the early osteoporosis research found

The article’s central study was published in Cell Metabolism in 2009. In the paper “Cannabinoid Receptor Type 1 Protects Against Age-Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells,” researchers studied mice that lacked the type 1 cannabinoid receptor, or CB1.

These mice initially had greater peak bone mass because of reduced bone resorption. As they aged, however, they developed features associated with osteoporosis, including reduced bone formation and increased accumulation of fat cells in the bone marrow. Their marrow stromal cells were less likely to develop into osteoblasts—the cells responsible for forming bone—and more likely to develop into adipocytes, or fat cells.

The findings suggest that CB1 signaling participates in bone remodeling and age-related bone loss. They do not show that smoking cannabis, taking medical marijuana or using a particular cannabis product prevents osteoporosis in humans. The study involved genetically modified mice, cultured cells and pharmacological experiments—not patients with osteoporosis.

CBD and fracture healing

A separate 2015 study examined whether individual cannabis compounds could affect the healing of an established fracture. In the Journal of Bone and Mineral Research paper on cannabidiol and fracture healing, researchers treated rats with cannabidiol (CBD), tetrahydrocannabinol (THC) or a combination of the two after mid-femur fractures.

CBD improved the maximum load and work-to-failure of healing femurs after eight weeks, indicating stronger and tougher repair tissue. The researchers linked this effect to increased expression of Plod1, an enzyme involved in collagen cross-linking and stabilization. CBD improved certain mechanical properties without substantially changing callus size or mineral density. THC alone did not produce the same benefit, and the combination of THC and CBD did not consistently improve outcomes over CBD alone.

These results are scientifically interesting but remain preclinical. A rat fracture model cannot establish that CBD prevents osteoporosis, increases bone density in people or improves healing after human fractures. It also does not demonstrate that whole-plant cannabis has the same effects as purified CBD.

Evidence involving pain and osteoarthritis

The article also cited a 2014 review, “Involvement of the Endocannabinoid System in Osteoarthritis Pain,” published in the European Journal of Neuroscience. The review described evidence from laboratory and animal studies suggesting that the endocannabinoid system may influence pain, inflammation and joint function.

That evidence concerns osteoarthritis pain, not osteoporosis itself. Osteoarthritis is a degenerative joint disease involving cartilage and pain, whereas osteoporosis primarily weakens bone and raises fracture risk. The review also emphasized that clinical evidence supporting cannabinoids for osteoarthritis pain was limited. Therefore, it should not be presented as proof that medical cannabis treats osteoporosis or as confirmation that it reliably relieves all bone-related pain.

What the evidence means for patients

Taken together, the studies point to possible roles for cannabinoid signaling in bone-cell activity and fracture repair. The strongest findings came from mice, rats and cell cultures. They provide hypotheses for future research rather than evidence of an established osteoporosis therapy.

People concerned about osteoporosis should discuss fracture-risk assessment, bone-density testing and appropriate treatment with a health professional. The MedlinePlus osteoporosis guide describes established approaches, including exercise, calcium and vitamin D as appropriate, smoking cessation, limiting alcohol, fall prevention and prescription medications when indicated.

Future human studies will need to determine whether specific cannabinoids affect bone density, bone quality, fracture healing or pain—and whether any potential benefits outweigh risks and medication interactions. Until those studies are available, it is more accurate to describe cannabinoids as an experimental area of bone research than as a proven treatment for osteoporosis.